HUP0203032A3 - Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use - Google Patents
Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0203032A3 HUP0203032A3 HU0203032A HUP0203032A HUP0203032A3 HU P0203032 A3 HUP0203032 A3 HU P0203032A3 HU 0203032 A HU0203032 A HU 0203032A HU P0203032 A HUP0203032 A HU P0203032A HU P0203032 A3 HUP0203032 A3 HU P0203032A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- crystalline form
- compositions containing
- dissolution rate
- Prior art date
Links
- 238000004090 dissolution Methods 0.000 title 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title 1
- 229960001208 eplerenone Drugs 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16968299P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US16969099P | 1999-12-08 | 1999-12-08 | |
| US16980799P | 1999-12-08 | 1999-12-08 | |
| PCT/US2000/032416 WO2001042272A2 (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203032A2 HUP0203032A2 (hu) | 2002-12-28 |
| HUP0203032A3 true HUP0203032A3 (en) | 2003-04-28 |
Family
ID=27558585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203032A HUP0203032A3 (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1177204A2 (enExample) |
| JP (1) | JP2003516414A (enExample) |
| KR (1) | KR100607923B1 (enExample) |
| CN (2) | CN1152886C (enExample) |
| AU (1) | AU784946B2 (enExample) |
| BR (1) | BR0008057A (enExample) |
| CA (1) | CA2362669A1 (enExample) |
| CO (1) | CO5280211A1 (enExample) |
| EA (1) | EA007934B1 (enExample) |
| HU (1) | HUP0203032A3 (enExample) |
| IL (3) | IL144764A0 (enExample) |
| MX (1) | MXPA01008056A (enExample) |
| MY (1) | MY131878A (enExample) |
| NO (1) | NO20013856L (enExample) |
| NZ (2) | NZ530028A (enExample) |
| PE (1) | PE20010917A1 (enExample) |
| WO (1) | WO2001042272A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1487540A2 (en) * | 2002-03-20 | 2004-12-22 | Pharmacia Corporation | Storage stable eplerenone formulation |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| CA2582496A1 (en) | 2007-03-20 | 2008-09-20 | Apotex Pharmachem Inc. | Improved process for the preparation and purification of eplerenone |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN108059648A (zh) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | 一种依普利酮溶剂合物及其制备方法 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
| WO2023204729A1 (ru) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции |
| CN120754115A (zh) * | 2025-05-23 | 2025-10-10 | 远大医药（中国）有限公司 | 一种含依普利酮组合物及其药物制剂、制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| NZ336004A (en) * | 1996-12-11 | 2001-04-27 | G | Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base |
| JP2002538172A (ja) * | 1999-03-05 | 2002-11-12 | ジー．ディー．サール エルエルシー | 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法 |
-
2000
- 2000-12-04 CN CNB008057788A patent/CN1152886C/zh not_active Expired - Fee Related
- 2000-12-04 HU HU0203032A patent/HUP0203032A3/hu unknown
- 2000-12-04 MX MXPA01008056A patent/MXPA01008056A/es not_active Application Discontinuation
- 2000-12-04 NZ NZ530028A patent/NZ530028A/en not_active IP Right Cessation
- 2000-12-04 EP EP00983781A patent/EP1177204A2/en not_active Withdrawn
- 2000-12-04 KR KR1020017010043A patent/KR100607923B1/ko not_active Expired - Fee Related
- 2000-12-04 WO PCT/US2000/032416 patent/WO2001042272A2/en not_active Ceased
- 2000-12-04 JP JP2001543569A patent/JP2003516414A/ja not_active Withdrawn
- 2000-12-04 EA EA200100871A patent/EA007934B1/ru not_active IP Right Cessation
- 2000-12-04 NZ NZ513961A patent/NZ513961A/xx not_active IP Right Cessation
- 2000-12-04 IL IL14476400A patent/IL144764A0/xx active IP Right Grant
- 2000-12-04 AU AU20492/01A patent/AU784946B2/en not_active Ceased
- 2000-12-04 CA CA002362669A patent/CA2362669A1/en not_active Abandoned
- 2000-12-04 CN CNA2004100368081A patent/CN1557833A/zh active Pending
- 2000-12-04 BR BR0008057-8A patent/BR0008057A/pt not_active IP Right Cessation
- 2000-12-06 MY MYPI20005734A patent/MY131878A/en unknown
- 2000-12-06 PE PE2000001300A patent/PE20010917A1/es not_active Application Discontinuation
- 2000-12-11 CO CO00094075A patent/CO5280211A1/es not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144764A patent/IL144764A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013856A patent/NO20013856L/no not_active Application Discontinuation
-
2006
- 2006-06-22 IL IL176511A patent/IL176511A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0008057A (pt) | 2002-04-23 |
| CN1377365A (zh) | 2002-10-30 |
| WO2001042272A9 (en) | 2002-12-12 |
| CA2362669A1 (en) | 2001-06-14 |
| WO2001042272A2 (en) | 2001-06-14 |
| IL144764A (en) | 2007-08-19 |
| MXPA01008056A (es) | 2003-07-21 |
| HUP0203032A2 (hu) | 2002-12-28 |
| NO20013856D0 (no) | 2001-08-08 |
| KR100607923B1 (ko) | 2006-08-04 |
| EA007934B1 (ru) | 2007-02-27 |
| KR20010112261A (ko) | 2001-12-20 |
| HK1050536A1 (en) | 2003-06-27 |
| PE20010917A1 (es) | 2001-09-10 |
| NZ513961A (en) | 2004-02-27 |
| NZ530028A (en) | 2005-08-26 |
| WO2001042272A3 (en) | 2001-11-29 |
| IL144764A0 (en) | 2002-06-30 |
| AU784946B2 (en) | 2006-08-03 |
| CN1152886C (zh) | 2004-06-09 |
| EA200100871A1 (ru) | 2002-04-25 |
| CN1557833A (zh) | 2004-12-29 |
| CO5280211A1 (es) | 2003-05-30 |
| JP2003516414A (ja) | 2003-05-13 |
| NO20013856L (no) | 2001-10-08 |
| EP1177204A2 (en) | 2002-02-06 |
| MY131878A (en) | 2007-09-28 |
| AU2049201A (en) | 2001-06-18 |
| IL176511A (en) | 2007-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300618A3 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0203548A3 (en) | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0203316A3 (en) | Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0204515A3 (en) | 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0203122A3 (en) | Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0300616A3 (en) | Adamantane derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0105114A2 (hu) | Kinazolinonszármazékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás az előállításukra | |
| HUP0303529A3 (en) | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0301069A3 (en) | Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0202731A3 (en) | O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0201516A3 (en) | 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0201753A3 (en) | Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0202075A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0201402A3 (en) | Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0203184A3 (en) | Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0203385A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0105481A3 (en) | Pharmaceutical compositions containing clarithromycin and process for their preparation and their use | |
| HUP0202934A3 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof | |
| HUP0204318A3 (en) | Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0201315A3 (en) | 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0201785A3 (en) | Dihydrobenzodiazepins, process for producing them, their use and pharmaceutical compositions containing them | |
| IL144764A0 (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate | |
| HUP0204394A3 (en) | Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |